Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

PRT3789, a First-in-Class Intravenous SMARCA2 Degrader, in Advanced Solid Tumors With a SMARCA4 Mutation: Phase 1 Trial

Monday, March 10, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a Phase 1 trial of PRT3789, an innovative intravenous SMARCA2 degrader, aimed at treating advanced solid tumors harboring a SMARCA4 mutation. This trial represents a significant step in targeting specific mutations in cancer therapy. The involvement of various experts highlights the collaborative effort in advancing this treatment.
Price reaction · baseline $0.736 (2025-03-07 close) · hit pre-market · clean, no other PRLD news in the window
day 0 close
-9%
day 1 · peak
-10.2%
day 3
-4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of a first-in-class intravenous SMARCA2 degrader.
  • Targeting advanced solid tumors with a specific mutation.
  • Potential for significant advancements in cancer treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

Timothy A. Yap, Afshin Dowlati, Ibiayi Dagogo-Jack, Julien Vibert, Alexander I. Spira, Victor Moreno, Salman R. Punekar, Emiliano Calvo, Guru P. Sonpavde, Mark Awad, Jonathan W. Riess, Tatiana Hernández-Guerrero, Benjamin Herzberg, Antoine Italiano, Aurelie Swalduz, Ticiana A Leal, Patricia LoRusso, Egbert F. Smit, Edward B. Garon, William Novotny, Robin Guo

Frequently Asked Questions

What is PRT3789?

PRT3789 is a first-in-class intravenous SMARCA2 degrader designed for cancer treatment.

What type of tumors does PRT3789 target?

It targets advanced solid tumors that have a SMARCA4 mutation.

What phase is the PRT3789 trial currently in?

The trial of PRT3789 is currently in Phase 1.

Who are the researchers involved in the trial?

The trial involves multiple experts, including Timothy A. Yap and Afshin Dowlati.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare PRT3789 SMARCA2 SMARCA4 solid tumors Phase 1 trial
Last updated: Mar 10, 2025

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →